title: [Radiotherapeutic quality assurance in the Hodgkin's disease study HD4 supported by the BMFT (Bundesministerium für Forschung und Technologie)].
abstract: In the German Hodgkin Study Group a radiotherapy assurance program is being carried out at the radiotherapeutic reference centre in Göttingen since April 1988: 74 patients were entered from 27 radiotherapeutic institutions. 18 of them participated in a quality assurance program and submitted the data of 29 patients: In 21 of the 29 patients the protocol was followed correctly. Physical aspects of quality control showed two major deviations from the protocol: one center used photon energies of more than 15 MVX without mould; another had a anterior-posterior loading of 3:1. The radiation oncology assessment detected six inadequate treatments: The safety margin was inappropriate in three of 26 mantle fields. Another center used a multiple field technique, and in two patients the paraaortic region was not irradiated.
authors.affiliation: Strahlentherapeutische Kliniken, Universitätskliniken Göttingen.
authors.forename: S L
authors.initials: SL
authors.lastname: Roth
authors.forename: E
authors.initials: E
authors.lastname: Dühmke
authors.forename: H
authors.initials: H
authors.lastname: Kirschner
authors.forename: N
authors.initials: N
authors.lastname: Willich
authors.forename: R P
authors.initials: RP
authors.lastname: Müller
authors.forename: A
authors.initials: A
authors.lastname: Bleher
authors.forename: M
authors.initials: M
authors.lastname: Pfreundschuh
authors.forename: M
authors.initials: M
authors.lastname: Löffler
authors.forename: V
authors.initials: V
authors.lastname: Diehl
mesh_terms: D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D005860:Germany, West; D006689:Hodgkin Disease / Q000532:radiotherapy*; D006801:Humans; D010315:Particle Accelerators; D011785:Quality Assurance, Health Care; D011867:Radioisotope Teletherapy; D011882:Radiotherapy, High-Energy
chemical_list: D003037:Cobalt Radioisotopes
vernacular_title: Radiotherapeutische Qualitätssicherung in der BMFT-Studie Morbus Hodgkin (HD4).